Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Hereditary Cancer Predisposition Syndromes.

J. Garber, K. Offit
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer genetics is increasingly becoming integrated into the practice of modern medical oncology. The ability to distinguish a growing proportion of the 5% to 10% of all cancers that develop in individuals who have inherited a genetic mutation conferring heightened susceptibility to specific cancers may permit targeted efforts in cancer surveillance and prevention. While these individuals comprise a small proportion of the overall burden of cancer, strategies successful in reducing their remarkable cancer risks may be generalizable to the broader population. In this review, we highlight the most common hereditary cancer syndromes, most attributable to genes inherited in an autosomal dominant manner with incomplete penetrance, and a number of rare syndromes in which particular progress has been made. The prevalence, penetrance, tumor spectrum, and underlying genetic defects are discussed and summarized in a large table in which a more comprehensive enumeration of syndromes is provided.
This paper references
10.1038/nrc1431
BRCA1 and BRCA2: 1994 and beyond
S. Narod (2004)
10.1016/S0016-5085(99)70510-X
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.
H. Vasen (1999)
The role of hPMS1 and hPMS2 in predisposing to colorectal cancer.
T. Liu (2001)
10.1200/JCO.20.6.1480
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
T. Frank (2002)
10.1007/s10350-004-6127-y
Attenuated Familial Adenomatous Polyposis
J. Church (2002)
10.1136/gut.50.6.857
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis
R. Phillips (2002)
10.1001/ARCHINTE.1989.00390120069014
Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands.
H. Vasen (1989)
10.1056/NEJM199808203390804
Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.
J. Wijnen (1998)
10.1016/0092-8674(93)90330-S
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
F. Leach (1993)
10.1093/ANNONC/MDG486
The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice.
F. Graziano (2003)
10.1086/318787
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H. Risch (2001)
10.1001/JAMA.283.17.2260
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J. Boyd (2000)
10.1016/S0039-6257(98)00019-8
Trilateral retinoblastoma: insights into histogenesis and management.
D. Marcus (1998)
10.1056/NEJMOA020119
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
N. Kauff (2002)
10.4065/75.1.57
Care of patients and their families with familial adenomatous polyposis.
J. King (2000)
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity.
A. Goldstein (1993)
10.1016/S0140-6736(03)12856-5
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
F. Lalloo (2003)
10.1056/NEJMRA012242
Hereditary colorectal cancer.
H. Lynch (1991)
COX-2 inhibition in clinical cancer prevention.
P. Lynch (2001)
10.1093/JNCI/95.3.180
Familial pancreatic cancer: where are we in 2003?
G. Petersen (2003)
10.1093/HMG/11.20.2347
The pressure rises: update on the genetics of phaeochromocytoma.
E. Maher (2002)
10.1097/00000658-200103000-00009
Familial Adenomatous Polyposis: Prevalence of Adenomas in the Ileal Pouch After Restorative Proctocolectomy
Y. Parc (2001)
10.1016/0092-8674(93)90538-2
Alleles of the APC gene: An attenuated form of familial polyposis
L. Spirio (1993)
10.1093/ANNONC/10.SUPPL_4.S69
Familial pancreatic cancer.
A. Klein (2001)
10.1093/JNCI/93.21.1633
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
L. Hartmann (2001)
10.1002/MPO.1213
RB1 genetic testing as a clinical service: a follow-up study.
J. G. Cohen (2001)
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
A. Whittemore (1997)
10.1093/JNCI/DJH034
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
A. Umar (2004)
10.1038/ng1107
The genetics and genomics of cancer
A. Balmain (2003)
10.1093/JNCI/89.1.83
Hereditary retinoblastoma, lipoma, and second primary cancers.
F. Li (1997)
10.1001/JAMA.280.14.1227
BRCA1 and medullary breast cancer.
F. Eisinger (1998)
10.1002/ajmg.c.30024
Retinoblastoma: Revisiting the model prototype of inherited cancer
D. Lohmann (2004)
10.1086/323658
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.
J. Cunningham (2001)
10.1002/1097-0142(197710)40:4+<1861::AID-CNCR2820400815>3.0.CO;2-9
Genetic and environmental interactions
L. Strong (1977)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1126/SCIENCE.1088759
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
M. King (2003)
10.1126/SCIENCE.8484122
Microsatellite instability in cancer of the proximal colon.
S. Thibodeau (1993)
10.1038/323643A0
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
S. Friend (1986)
10.1016/S0165-4608(96)00290-7
An update of HNPCC (Lynch syndrome).
H. Lynch (1997)
10.1097/00005392-199909010-00004
Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma.
M. Walther (1999)
10.1093/JNCI/DJG072
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
K. Offit (2003)
10.1016/S0140-6736(03)13643-4
von Hippel-Lindau disease
R. Lonser (2003)
10.1056/NEJM196005052621803
Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome.
R. Gorlin (1960)
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
K. Murphy (2002)
10.1001/JAMA.1997.03540360065034
Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2
W. Burke (1997)
10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9
E‐cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer
P. Guilford (1999)
10.1093/JNCI/94.16.1221
On the use of familial aggregation in population-based case probands for calculating penetrance.
C. Begg (2002)
10.1002/GEPI.1102
Evidence for a major gene influencing risk of pancreatic cancer
A. Klein (2002)
10.1126/science.272.5268.1668
Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome
R. Johnson (1996)
10.1001/JAMA.292.11.1368
Breast MRI for women with hereditary cancer risk.
M. Robson (2004)
10.1038/ng853
Polygenic susceptibility to breast cancer and implications for prevention
P. Pharoah (2002)
10.1086/303076
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
M. Unger (2000)
10.1056/NEJMOA030660
The influence of finasteride on the development of prostate cancer.
I. Thompson (2003)
10.1038/bjc.1997.328
Li-Fraumeni syndrome--a molecular and clinical review.
J. Varley (1997)
10.1093/JNCI/92.15.1260
High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families
Åke Borg (2000)
10.1038/386804A0
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
S. Sharan (1997)
10.1056/NEJM198905253202102
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p.
S. Bale (1989)
10.1210/JCEM.86.12.8070
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
M. Brandi (2001)
10.1136/jmg.30.6.460
Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.
D. Evans (1993)
10.1093/HMG/8.8.1461
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
D. Marsh (1999)
10.1038/368258A0
Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer
C. E. Bronner (1994)
10.1182/BLOOD-2002-07-2170
A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
D. Kutler (2003)
10.1016/S0016-5085(02)80140-8
Hereditary diffuse gastric cancer: more answers or more questions?
W. Grady (2002)
10.1182/BLOOD-2003-09-3138
Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.
J. Wagner (2004)
Surveillance and Management of Patients at High Genetic Risk for Ovarian Carcinoma
H. Lynch (1982)
10.1053/GAST.2001.25581
AGA technical review on hereditary colorectal cancer and genetic testing.
F. Giardiello (2001)
10.1002/(SICI)1097-0142(19960715)78:2<199::AID-CNCR2>3.0.CO;2-H
Prophylactic colectomy for gene carriers in hereditary nonpolyposis colorectal cancer: Has the time come?
M. Rodriguez-Bigas (1996)
10.1093/JNCI/91.15.1310
Cancer risks in BRCA2 mutation carriers.
H. Olsson (1999)
10.1126/SCIENCE.7545954
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y. Miki (1994)
10.1016/S0022-5347(05)64541-7
Hereditary prostate cancer: clinical aspects.
O. Bratt (2002)
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
R. Eeles (2000)
10.1006/GYNO.2002.6673
General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome.
L. Strong (2003)
10.3322/CANJCLIN.43.3.134
The benefit and cost of prostate cancer early detection
P. Littrup (1993)
10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U
Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden)
H. Vasen (2000)
10.1016/S0022-3468(96)90343-7
Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.
M. Skinner (1996)
10.1038/378789A0
Identification of the breast cancer susceptibility gene BRCA2
R. Wooster (1995)
10.1056/NEJM198501103120205
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome.
M. Greene (1985)
10.1001/JAMA.284.7.857
Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps.
S. Syngal (2000)
10.1093/JNCI/89.23.1758
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines.
M. Rodriguez-Bigas (1997)
10.1200/JCO.1999.17.11.3653
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
K. Phillips (1999)
10.1158/1078-0432.CCR-03-0604
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
T. Kirchhoff (2004)
10.1126/SCIENCE.1651562
Identification of FAP locus genes from chromosome 5q21.
K. Kinzler (1991)
10.1001/JAMA.277.12.997
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
W. Burke (1997)
10.1002/cncr.11310
Improved survival in women with BRCA‐associated ovarian carcinoma
I. Cass (2003)
Fanconi anemia gene mutations in young-onset pancreatic cancer.
M. S. van der Heijden (2003)
Study of a single BRCA2 mutation with high carrier frequency in a small population.
S. Thorlacius (1997)
10.7326/0003-4819-134-4-200102200-00016
Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma
K. Pacak (2001)
10.1056/NEJM199808133390702
Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
S. Narod (1998)
10.1002/HUMU.10185
Germline TP53 mutations and Li‐Fraumeni syndrome
J. Varley (2003)
10.1093/JNCI/DJG024
Pheochromocytoma: the expanding genetic differential diagnosis.
Jennifer Bryant (2003)
10.1056/NEJM200106213442504
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.
D. Huntsman (2001)
10.1093/JNCI/94.23.1773
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
S. Narod (2002)
10.1086/339692
A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34.
M. Eberle (2002)
10.1056/NEJM199205143262001
Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.
J. Toguchida (1992)
10.1126/SCIENCE.8484121
Clues to the pathogenesis of familial colorectal cancer.
L. Aaltonen (1993)
10.7326/0003-4819-71-4-747
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
F. Li (1969)
10.1097/00005792-198703000-00002
Nevoid Basal Cell Carcinoma Syndrome
R. Gorlin (1987)
10.1097/00005792-199711000-00001
Von Hippel-Lindau disease.
W. Kaelin (2007)
10.1016/S0016-5085(00)70168-5
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.
H. Järvinen (2000)
10.1002/BJS.1800811207
Familial adenomatous polyposis
W. Campbell (1994)
10.1136/JMG.37.11.828
Will the real Cowden syndrome please stand up: revised diagnostic criteria.
C. Eng (2000)
10.1111/j.1749-6632.2002.tb04337.x
Role of PTEN, a Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis
C. Eng (2002)
10.1056/NEJM200107193450301
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H. Meijers-Heijboer (2001)
10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L
Cancer risk in mutation carriers of DNA‐mismatch‐repair genes
M. Aarnio (1999)
10.1126/SCIENCE.275.5308.1943
PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
J. Li (1997)
10.1023/A:1023299520828
Genetic susceptibility to prostate cancer: a review
Bas A. J. Verhage (2004)
10.1056/NEJM199906173402404
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
G. Eisenhofer (1999)
10.1086/318181
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.
D. Thompson (2001)
10.1136/jmg.39.8.611
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families
N. Kauff (2002)
10.1016/S1097-2765(01)00173-3
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
I. García-Higuera (2001)
10.1001/JAMA.292.8.943
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
H. P. Neumann (2004)
10.1056/NEJM200107263450401
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
B. Modan (2001)
Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM).
L. Cannon-Albright (1994)
10.1056/NEJMOA012158
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
T. Rebbeck (2002)
10.1056/NEJMOA031759
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
M. Kriege (2004)
10.1200/JCO.2003.09.118
Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis.
L. Bertario (2003)
10.1016/S0022-5347(17)36733-2
A screening study of prostate cancer in high risk families.
W. McWhorter (1992)
10.1002/1097-0142(20010701)92:1<181::AID-CNCR1307>3.0.CO;2-J
Germline E‐cadherin gene mutations
Y. Chun (2001)
10.1093/JNCI/94.12.894
Geographical variation in the penetrance of CDKN2A mutations for melanoma.
D. Bishop (2002)
Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial
C. Kuhl (2003)
10.1086/514845
Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma.
D. Lohmann (1997)
10.1177/019459989411100122
Malignant Potential of the Odontogenic Keratocyst
V. Anand (1994)
10.1200/JCO.2003.03.189
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
Adopted on March (2003)
10.1093/MOLEHR/GAG014
First preimplantation genetic diagnosis of hereditary retinoblastoma using informative microsatellite markers.
A. Girardet (2003)
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
C. Boland (1998)
Prophylactic oophorectomy in inherited breast/ovarian cancer families.
J. Struewing (1995)
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
K. Nichols (2001)
A cancer family syndrome in twenty-four kindreds.
F. Li (1988)
10.1097/00004836-198610000-00019
Cowden disease. A hereditary polyposis syndrome diagnosable by mucocutaneous inspection.
A. Hover (1986)
10.1016/S0140-6736(00)03258-X
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
S. Narod (2000)
10.1093/JNCI/95.3.214
BRCA2 Germline Mutations in Familial Pancreatic Carcinoma
S. Hahn (2003)
10.1200/JCO.2004.06.940
MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie.
K. Offit (2004)
10.1002/HUMU.9289
Spectrum of PTCH mutations in Italian nevoid basal cell‐carcinoma syndrome patients: Identification of thirteen novel alleles
M. Savino (2004)
10.1016/0092-8674(93)90546-3
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
R. Fishel (1993)
10.1093/JNCI/DJH058
Lifetime risks of common cancers among retinoblastoma survivors.
O. Fletcher (2004)
10.1111/j.1572-0241.2006.00375.x
Familial Adenomatous Polyposis
P. Galiatsatos (2006)
10.1056/NEJMOA025283
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH.
O. Sieber (2003)
10.1001/JAMA.292.11.1317
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
E. Warner (2004)
10.1126/SCIENCE.286.5449.2528
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
D. Bell (1999)
10.1016/S0140-6736(98)85011-3
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
U. Veronesi (1998)
10.1056/NEJM200106213442511
The power of genetics to target surgical prevention.
J. Weitzel (2001)
10.1038/NM0296-169
Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients
Bo Liu (1996)
10.1073/PNAS.68.4.820
Mutation and cancer: statistical study of retinoblastoma.
A. Knudson (1971)
10.1001/ARCHOPHT.119.11.1699
Molecular basis of low-penetrance retinoblastoma.
J. Harbour (2001)
10.1093/JNCI/89.2.166
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
S. Ingles (1997)
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.
J. Cunningham (1998)
10.1038/NG0994-22
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
A. Kamb (1994)
10.1038/sj.onc.1207591
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families
E. Hensen (2004)
10.1086/375033
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A. Antoniou (2003)
10.1126/SCIENCE.276.5311.404
Positional cloning of the gene for multiple endocrine neoplasia-type 1.
S. Chandrasekharappa (1997)
10.1001/JAMA.277.11.915
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.
W. Burke (1997)
10.1136/jmg.2004.018275
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria
A. Brooks-Wilson (2004)
Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident.
C. Wicking (1997)
Association of prostate cancer with vitamin D receptor gene polymorphism.
J. Taylor (1996)
10.1016/S0016-5085(03)84094-5
Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone
A. Charlton (2003)
10.1038/NG0196-97
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
L. Zuo (1996)
10.1126/SCIENCE.287.5454.848
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.
B. Baysal (2000)
10.1016/0016-5085(95)90688-6
Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer.
H. Järvinen (1995)
10.1136/jmg.38.3.159
Male breast cancer in Cowden syndrome patients with germlinePTEN mutations
J. Fackenthal (2001)
10.1126/SCIENCE.1439824
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.
L. Cannon-Albright (1992)
10.1002/GEPI.1370030104
Segregation analysis of hereditary nonpolyposis colorectal cancer
Joan E. Bailey‐wilson (1986)
10.1158/0008-5472.CAN-03-3823
Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds
A. Klein (2004)
10.1200/JCO.20.4.1043
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.
N. Lindor (2002)
10.1053/J.GASTRO.2004.05.003
Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.
R. Burt (2004)
10.1136/gut.35.9.1262
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols.
H. Vasen (1994)
Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma.
H. Z. Noorani (1996)
10.1001/JAMA.1997.03540350065035
Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer
W. Burke (1997)
10.1016/S0140-6736(95)91016-6
Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome)
H. Vasen (1995)
10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#
Extracolonic cancer in hereditary nonpolyposis colorectal cancer
P. Watson (1993)
10.1158/1078-0432.CCR-1029-3
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
S. Lakhani (2004)
10.1034/j.1399-0004.2000.580201.x
Hereditary colorectal cancer: risk assessment and management
H. Hampel (2000)
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
G. Lal (2000)
NCCN Practice Guidelines for Colorectal Cancer.
A. Benson (2000)
10.1001/JAMA.1978.03280350068019
Precursor Lesions in Familial Melanoma: A New Genetic Preneoplastic Syndrome
R. Reimer (1978)
10.1200/JCO.2003.04.131
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
D. Levine (2003)
10.1093/HMG/6.7.1051
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
E. Woodward (1997)
10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
P. Chappuis (2000)
10.1056/NEJMOA020152
Germ-line mutations in nonsyndromic pheochromocytoma.
H. Neumann (2002)
10.1126/SCIENCE.1073834
Biallelic Inactivation of BRCA2 in Fanconi Anemia
N. G. Howlett (2002)
10.1001/JAMA.276.19.1575
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C. Eng (1996)
10.1056/NEJM199510123331504
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
A. Goldstein (1995)
10.1126/science.274.5291.1371
Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search
J. Smith (1996)
10.1093/JNCI/85.14.1121
Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma
C. Eng (1993)
10.1086/514861
Predictive testing for retinoblastoma comes of age.
B. Gallie (1997)
10.1038/bjc.1997.354
The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma.
R. Cowan (1997)
10.1385/1-59259-328-3:117
TP53, hChk2, and the Li-Fraumeni syndrome.
J. Varley (2003)
10.1038/NG0997-79
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
S. Laken (1997)
10.1016/0959-8049(94)00387-K
Multiple endocrine neoplasia type 1 (MEN1).
J. Pang (1994)
10.1016/S1470-2045(04)01469-X
Clinical germline genetic testing for melanoma.
C. B. Hansen (2004)
10.1038/sj.onc.1202033
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome
J. Birch (1998)
10.1056/NEJMOA012015
Primary chemoprevention of familial adenomatous polyposis with sulindac.
F. Giardiello (2002)
10.1016/S1472-6483(10)61617-3
Preimplantation genetic diagnosis for cancer predisposition.
S. Rechitsky (2002)
10.1097/00000421-199110000-00018
Primary breast cancer after prophylactic mastectomy.
L. Ziegler (1991)
10.1086/301749
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D. Ford (1998)



This paper is referenced by
10.1016/j.soncn.2010.11.004
Germline mutations in cancer susceptibility genes: an overview for nurses.
D. Macdonald (2011)
10.1186/1471-2350-9-52
The association between genetic variants in hMLH1 and hMSH2 and the development of sporadic colorectal cancer in the Danish population
L. L. Christensen (2007)
10.1007/978-3-319-72619-9
Age of Onset of Mental Disorders
Girolamo (2019)
10.1038/modpathol.2016.135
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort
K. Ring (2016)
10.4251/wjgo.v7.i5.30
Epigenetic reduction of DNA repair in progression to gastrointestinal cancer.
C. Bernstein (2015)
10.1016/J.CANCERGENCYTO.2007.07.014
Exclusion of APC and VHL gene deletions by array-based comparative hybridization in two patients with microscopically visible chromosomal aberrations.
R. Wallerstein (2007)
10.1002/pbc.26441
The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation
C. Goudie (2017)
10.1200/JCO.2009.25.7816
Genome-wide association studies of cancer.
Z. Stadler (2010)
10.1016/j.ctrv.2010.03.006
Targeting DNA repair in breast cancer: a clinical and translational update.
E. Amir (2010)
10.18597/RCOG.368
Síndrome de cáncer hereditario de mama y ovario: aplicación clínica
Laura Yuriko González-Teshima (2016)
10.1038/s41571-019-0179-3
Therapeutic implications of germline genetic findings in cancer
S. Thavaneswaran (2019)
10.1016/j.ygyno.2018.04.564
Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
D. Nebgen (2018)
MEETING REPORT Update on Pediatric Cancer Predisposition Syndromes
Joshua D Schiffman (2013)
10.2147/CLEP.S159183
Parental age and risk of genetic syndromes predisposing to nervous system tumors: nested case–control study
Maral Adel Fahmideh (2018)
10.4172/2161-0711.1000255
Referral of Patients with Suspected Hereditary Breast-Ovarian Cancer or Lynch Syndrome for Genetic Services: A Systematic Review
Yen Y. Tan (2013)
10.1016/j.dld.2018.12.003
Risk and survival of third primary cancers in a population-based cohort of gastric cancer patients.
S. Morais (2019)
10.1111/eve.12744
Calcitonin as a potential tumour marker for medullary thyroid carcinoma in an 11‐year‐old Spanish Pure Bred gelding with two independent carcinomas
N. Dittus (2018)
10.1016/J.BIOCEL.2006.08.005
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Telma Crugliano (2007)
10.1007/S10332-006-0113-7
Organisation de la consultation et rôle de l’infirmière en oncogénétique: le modèle suisse
A. E. Murphy (2006)
10.1007/s10897-005-9006-3
On Using a Cancer Center Cancer Registry to Identify Newly Affected Women Eligible for Hereditary Breast Cancer Syndrome Testing: Practical Considerations
Tiffani A. DeMarco (2005)
10.1007/s10689-014-9749-9
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing
Y. Guan (2014)
10.1038/ncpgasthep1235
Managing hereditary gastrointestinal cancer syndromes: the partnership between genetic counselors and gastroenterologists
W. Rubinstein (2008)
10.1038/s41598-020-63764-4
SEER and Gene Expression Data Analysis Deciphers Racial Disparity Patterns in Prostate Cancer Mortality and the Public Health Implication
W. Zhang (2020)
10.14744/nci.2017.38980
Integrating personalized genomics into Turkish healthcare system: A cancer-oriented pilot activity of Istanbul Northern Anatolian Public Hospitals with GLAB
L. Doğanay (2017)
10.1080/02688697.2018.1522415
The role of ABO blood groups in glial neoplasms
A. Alkan (2019)
10.1093/ANNONC/MDI326
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
10.1038/nrc.2017.5
Tissue-specific tumorigenesis: context matters
Günter Schneider (2017)
10.3109/9781420052886-2
Clinical Relevance of Hereditary Ovarian Cancer
J. Lancaster (2008)
10.7202/011962AR
Prédispositions génétiques aux cancers : actualités et perspectives en 2005
D. Stoppa-Lyonnet (2005)
10.1002/cncr.31331
Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panels
C. Dinardo (2018)
10.18535/JMSCR/V7I3.76
Analysis of Multiple Primary Malignant Neoplasms: A Report from a Tertiary Cancer Centre in South India
K. Jayaraman (2019)
10.1038/nrc3298
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
R. Gillies (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar